Literature DB >> 11084292

Dopamine induces proteasome inhibition in neural PC12 cell line.

J N Keller1, F F Huang, E R Dimayuga, W F Maragos.   

Abstract

The autoxidation and enzymatic catabolism of dopamine results in the generation of reactive oxygen species (ROS), which may possibly contribute to oxidative stress in multiple neurodegenerative disorders. Recent studies indicate that proteasome inhibition occurs in numerous neurodegenerative conditions, possibly as the result of oxidative stress, although the effects of dopamine on proteasome activity have not been determined. In the present study we examined the effects of dopamine on proteasome activity in the neural PC12 cell line. Application of dopamine induced a dose- and time-dependent decrease in proteasome activity, which occurred prior to cell death. Application of an antioxidant (gluthathione monoethyl ester), monoamine oxidase inhibitors (deprenyl, clogyline, paragyline), or an inhibitor of dopamine uptake (nomifensine) attenuated dopamine toxicity and dopamine-induced proteasome impairment. Application of the proteasome inhibitor lactacystin increased the toxicity of dopamine and the levels of protein oxidation following administration of dopamine. Together, these data indicate that dopamine induces proteasome inhibition that is dependent, in part, on ROS and dopamine uptake, and suggest a possible role for proteasome inhibition in dopamine toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084292     DOI: 10.1016/s0891-5849(00)00412-3

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  20 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

Review 2.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 3.  Killer proteases and little strokes--how the things that do not kill you make you stronger.

Authors:  Anne E O'Duffy; Yvette M Bordelon; BethAnn McLaughlin
Journal:  J Cereb Blood Flow Metab       Date:  2006-08-09       Impact factor: 6.200

4.  Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.

Authors:  Hanoch Elkon; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

5.  Role of calcium independent phospholipase A2 in maintaining mitochondrial membrane potential and preventing excessive exocytosis in PC12 cells.

Authors:  May-Thu Ma; Jin-Fei Yeo; Akhlaq A Farooqui; Wei-Yi Ong
Journal:  Neurochem Res       Date:  2010-11-30       Impact factor: 3.996

Review 6.  Disruption of protein quality control in Parkinson's disease.

Authors:  Casey Cook; Caroline Stetler; Leonard Petrucelli
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

7.  Enhanced toxicity to the catecholamine tyramine in polyglutamine transfected SH-SY5Y cells.

Authors:  Rebecca R Smith; Edgardo R Dimayuga; Jeffrey N Keller; William F Maragos
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

8.  Compromised proteasome degradation elevates neuronal nitric oxide synthase levels and induces apoptotic cell death.

Authors:  Philip Y Lam; Enrique Cadenas
Journal:  Arch Biochem Biophys       Date:  2008-08-05       Impact factor: 4.013

Review 9.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.